Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar

The primary objective of this study was to document the hospitalization rate due to respiratory syncytial virus (RSV) and compliance with palivizumab use in preterm infants receiving palivizumab immunoprophylaxis during 2009-2012 RSV seasons. This is a descriptive single-center cohort study. Infants...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2018-01, Vol.11, p.41-46
Main Authors: Abushahin, Ahmad, Janahi, Ibrahim, Tuffaha, Amjad
Format: Article
Language:English
Subjects:
Analysis
BPD
Bronchiolitis
Bronchopulmonary dysplasia
Care and treatment
Congenital diseases
Congenital heart disease
Dosage and administration
Dysplasia
Epidemiology
FDA approval
Health aspects
Hospitalization
Immunization
Immunotherapy
Infants
Monoclonal antibodies
Multiple births
Original Research
Palivizumab
Premature babies
Premature infants
Preterm
Respiratory syncytial virus
Respiratory tract diseases
Risk factors
RSV
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The primary objective of this study was to document the hospitalization rate due to respiratory syncytial virus (RSV) and compliance with palivizumab use in preterm infants receiving palivizumab immunoprophylaxis during 2009-2012 RSV seasons. This is a descriptive single-center cohort study. Infants who were ≤35-week gestational age were eligible for enrollment if they received the first palivizumab dose between November 1 and March 31 (2009-2010, 2010-2011, 2011-2012). Primary endpoint was defined as RSV hospitalization of duration 24 hours or longer. The cumulative RSV hospitalization rate in the registry (2009-2012) was 1.9%. The compliance rate was 85.7%. It showed steady increase across the 3 successive RSV seasons, 2009-2010, 2010-2011, and 2011-2012 (57.7% vs 92.6%, 94.2%, respectively,
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S156078